The Federal Trade Commission said pharmacy benefit managers created a "perverse drug rebate system" that artificially ...

Recent developments in health include EU approval of Novo's Wegovy for obesity-related heart conditions, the US FDA's nod for ...

Novo Nordisk, tje manufacturer behind Ozempic and Wegovy has another weight loss medication in the works — but according to ...

Pemvidutide's potential in obesity and MASH, combined with lean mass preservation, could make it a market leader in the ...

We’re firmly in the “buyer beware” era of obesity drugs. And unfortunately, it seems like we’re going to be stuck here for a ...

The agency alleges CVS’s Caremark, Cigna’s Express Scripts and UnitedHealth’s Optum Rx accepted money from drugmakers in ...

Discounts of as much as half on the $1,000-plus-a-month injectables are meant to induce insurers to offer coverage to workers ...

The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

The latest health news covers the European Medicines Agency's approval of Novo Nordisk's Wegovy for heart conditions linked ...

Health-care company stocks fell as U.S. regulators look to crack down on prices and companies battle over market share of popular drugs. The Federal Trade Commission sued the drug middlemen that ...

A next-generation obesity drug candidate from Novo Nordisk produced modest weight loss, along with a higher rate of some ...

The Federal Trade Commission (FTC) on Friday sued the three largest pharmacy benefit managers (PBMs) for engaging in alleged ...